Review argues spontaneous equine sarcoid regression is rare

A new review in Equine Veterinary Journal is sharpening the conversation around one of equine practice’s most frustrating skin tumors: spontaneous regression of equine sarcoids. In the March 2026 paper, Sabine Brandt concludes that self-resolution should be considered exceptional, pushing back on any broad assumption that sarcoids will commonly disappear on their own. (beva.onlinelibrary.wiley.com)

That matters because sarcoids are the most common skin tumors in horses, and they sit at the intersection of oncology, dermatology, surgery, and immunology. They’re benign in the metastatic sense, but they can be locally aggressive, anatomically difficult, and prone to recurrence. Brandt’s review describes sarcoids as linked to bovine papillomavirus, especially BPV-1 and BPV-2, with BPV-13 also implicated, and notes that impaired immune responses may help explain why these lesions often persist. (researchgate.net)

The review also arrives against a backdrop of active treatment development. On May 29, 2026, the Focused Ultrasound Foundation announced a world-first clinical trial at the Virginia-Maryland College of Veterinary Medicine evaluating histotripsy, a non-thermal focused ultrasound technique, for equine sarcoids. The five-horse feasibility study, led by Sophie Bogers, will treat sarcoids and then surgically remove them 24 hours later to assess tissue and immune effects. The launch of that trial underscores how persistent the unmet need remains in sarcoid management. (fusfoundation.org)

Still, the evidence base around “spontaneous regression” is not settled. A 2024 systematic review of equine sarcoid treatments found substantial heterogeneity and risk of bias across studies, but noted that spontaneous regression without treatment is reasonably frequently reported and may occur in up to 48% of cases, particularly in young horses. A longitudinal study of 61 Franches-Montagnes horses similarly reported that sarcoids disappeared without therapy in 29 of 38 affected horses over 5 to 7 years, especially in milder disease phenotypes. (beva.onlinelibrary.wiley.com)

That tension has already prompted visible scholarly pushback. In an April 2026 correspondence, Christoph Koch, Maarten Haspeslagh, Ann Martens, and Vince Gerber argued that the available evidence does not support labeling spontaneous regression as purely exceptional. They pointed to a prospective 14-month study in which about 25% of sarcoids regressed, with 12% resolving completely, and to a placebo-controlled trial in which complete regression occurred in 16% of placebo-treated sarcoids over 6 months. The same authors also argued that spontaneous regression is highly relevant to study design because untreated or placebo-controlled cohorts remain scarce, making therapeutic efficacy harder to interpret. (researchgate.net)

Why it matters: For veterinary professionals, the practical takeaway is less about choosing sides in an academic dispute and more about tightening case selection, client communication, and interpretation of outcomes. Brandt’s review supports a cautious stance: most sarcoids should still be approached as persistent lesions that may worsen, recur, or become harder to manage depending on type and location. But the response letter and prior longitudinal data suggest there may be subsets, especially younger horses with milder occult or verrucous lesions, where conservative monitoring can be a defensible option if the lesion is not compromising welfare, function, or treatment timing. (beva.onlinelibrary.wiley.com)

The bigger research implication is that spontaneous change in sarcoids can confound treatment claims. The 2024 systematic review found reported regression rates varied widely across therapies, while study quality was often limited. That means clinicians should read sarcoid treatment literature with a close eye on controls, diagnostic confirmation, follow-up duration, and lesion phenotype before translating reported success rates into practice. (abvp.com)

What to watch: The next signals to watch are whether the debate in Equine Veterinary Journal produces further clarification around which lesions are most likely to regress, and whether new interventional approaches such as histotripsy can offer lower-morbidity options for anatomically challenging or recurrent sarcoids. With the Virginia Tech pilot now underway as of May 2026, more prospective data may start to fill some of the evidence gaps that have complicated sarcoid decision-making for years. (fusfoundation.org)